- Home
- NRIX vs MYGN Comparison
NRIX vs MYGN Comparison
Compare NRIX & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- MYGN
- Stock Information
- Founded
- NRIX 2009
- MYGN 1991
- Country
- NRIX United States
- MYGN United States
- Employees
- NRIX N/A
- MYGN N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NRIX Health Care
- MYGN Health Care
- Exchange
- NRIX Nasdaq
- MYGN Nasdaq
- Market Cap
- NRIX 750.4M
- MYGN 756.5M
- IPO Year
- NRIX 2020
- MYGN 1995
- Fundamental
- Price
- NRIX $12.94
- MYGN $8.04
- Analyst Decision
- NRIX Strong Buy
- MYGN Hold
- Analyst Count
- NRIX 14
- MYGN 13
- Target Price
- NRIX $26.29
- MYGN $13.50
- AVG Volume (30 Days)
- NRIX 1.9M
- MYGN 901.6K
- Earning Date
- NRIX 10-09-2025
- MYGN 11-03-2025
- Dividend Yield
- NRIX N/A
- MYGN N/A
- EPS Growth
- NRIX N/A
- MYGN N/A
- EPS
- NRIX N/A
- MYGN N/A
- Revenue
- NRIX $83,687,000.00
- MYGN $832,900,000.00
- Revenue This Year
- NRIX $58.48
- MYGN $0.06
- Revenue Next Year
- NRIX N/A
- MYGN $5.68
- P/E Ratio
- NRIX N/A
- MYGN N/A
- Revenue Growth
- NRIX 48.32
- MYGN 3.83
- 52 Week Low
- NRIX $8.18
- MYGN $3.76
- 52 Week High
- NRIX $29.56
- MYGN $22.81
- Technical
- Relative Strength Index (RSI)
- NRIX 70.14
- MYGN 57.57
- Support Level
- NRIX $11.37
- MYGN $7.76
- Resistance Level
- NRIX $13.24
- MYGN $8.18
- Average True Range (ATR)
- NRIX 0.83
- MYGN 0.37
- MACD
- NRIX 0.28
- MYGN -0.03
- Stochastic Oscillator
- NRIX 92.80
- MYGN 43.59
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.